A2ATJ7 Pernix Therapeutics Holdings

Pernix Therapeutics to Report Third Quarter 2018 Financial Results on Thursday, November 8

Pernix Therapeutics to Report Third Quarter 2018 Financial Results on Thursday, November 8

MORRISTOWN, N.J., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced today that the Company will report financial results for the third quarter and nine months ended September 30, 2018, after the market close on Thursday, November 8, 2018.  Pernix management will also host a conference call at 4:30 pm Eastern Time to discuss the results.

Date:Thursday, November 8
Time:4:30 PM ET
Toll free (U.S.):866-548-4713
International:323-794-2093
Conference ID:9549306
Webcast:



About Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics Holdings, Inc. (the “Company”) is the parent company of Pernix Therapeutics, LLC, a specialty pharmaceutical business focused on acquiring and commercializing prescription drugs, primarily for the U.S. market.  Pernix Therapeutics, LLC is currently focused on the therapeutic areas of Pain and Neurology, and has an interest in expanding into additional specialty segments.  Pernix Therapeutics, LLC promotes branded products to physicians through its internal sales force.  The Company’s wholly-owned subsidiaries, Macoven Pharmaceuticals, L.L.C., and Cypress Pharmaceuticals, Inc., market a portfolio of generic products.  

To learn more about Pernix Therapeutics, visit

CONTACT

Investor Relations

Bob Yedid

LifeSci Advisors, LLC

EN
02/11/2018

Underlying

A2ATJ7Pernix Therapeutics Holdings

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pernix Therapeutics Holdings

 PRESS RELEASE
Free
A2ATJ7 Pernix Therapeu...

Pernix Therapeutics Holdings, Inc. Enters into Asset Purchase Agreemen...

Pernix Therapeutics Holdings, Inc. Enters into Asset Purchase Agreement with Certain Funds Managed by Highbridge Capital Management Transaction that includes the sale of substantially all of Pernix’s assets to be valued at $75.6 million             Pernix voluntarily files for Chapter 11 protection Pernix intends to continue to operate with no disruption to the availability of Pernix products and patient support services MORRISTOWN, N.J., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) (“Pernix” or the “Company”), a holding company that owns several ...

February 19, 2019 1 EN
 PRESS RELEASE
Free
A2ATJ7 Pernix Therapeu...

Pernix® Therapeutics Reports Third Quarter 2018 Financial Results

Pernix® Therapeutics Reports Third Quarter 2018 Financial Results MORRISTOWN, N.J., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced today its financial results for the three and nine months ended September 30, 2018. Third Quarter 2018 Financial Highlights The third quarter of 2018 represented the first quarter that fully consolidated the financial results of Nalpropion™ Pharmaceuticals, Inc., which are discussed in more detail below.Third quarter 2018 net revenues were $37.2 million, an 8% decrease...

November 8, 2018 1 EN
 PRESS RELEASE
Free
A2ATJ7 Pernix Therapeu...

Pernix Therapeutics to Report Third Quarter 2018 Financial Results on ...

Pernix Therapeutics to Report Third Quarter 2018 Financial Results on Thursday, November 8 MORRISTOWN, N.J., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced today that the Company will report financial results for the third quarter and nine months ended September 30, 2018, after the market close on Thursday, November 8, 2018.  Pernix management will also host a conference call at 4:30 pm Eastern Time to discuss the results. Date:Thursday, November 8Time:4:30 PM ETToll free (U.S.):866-548-4713International:32...

November 2, 2018 1 EN
 PRESS RELEASE
Free
A2ATJ7 Pernix Therapeu...

Pernix Therapeutics Holdings, Inc.’s Subsidiaries File Notice of App...

Pernix Therapeutics Holdings, Inc.’s Subsidiaries File Notice of Appeal in Patent Litigation Concerning Zohydro® ER with BeadTek® MORRISTOWN, N.J., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), announced today that, on September 7, 2018, its subsidiaries, Pernix Therapeutics, LLC, a specialty pharmaceutical company, and Pernix Ireland Pain Designated Activity Company, filed a notice of appeal to the United States Court of Appeals for the Federal Circuit in the Company’s litigation against Alvogen Malta Operations, Ltd. (Alvogen). The litigation rela...

September 12, 2018 1 EN
 PRESS RELEASE
Free
A2ATJ7 Pernix Therapeu...

Pernix Therapeutics Announces Ruling in Patent Litigation Concerning Z...

Pernix Therapeutics Announces Ruling in Patent Litigation Concerning Zohydro® ER with BeadTek® MORRISTOWN, N.J., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced today that in the Company’s litigation against Alvogen Malta Operations, Ltd. (Alvogen), the United States District Court for the District of Delaware found the asserted claims of U.S. Patent Nos. 9,265,760 and 9,339,499, which relate to methods of treating patients with mild and moderate hepatic impairment with hydrocodone bitartrate, to be infringe...

August 27, 2018 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch